title: Oxygen and estrogen.
abstract: Every so often, a bioethics controversy emerges that galvanizes our views. The Surfactant, Positive Pressure, and Oxygenation Randomized Trial mushroomed into a controversy of this sort this past year. In 2007, the "Ashley case," involving the use of estrogen to attenuate the growth of a girl with profound disabilities, was similarly controversial. Some of the lessons from that debate, in which I was centrally involved, may help advance the discussion about SUPPORT.
authors.forename: Benjamim S
authors.initials: BS
authors.lastname: Wilfond
mesh_terms: D006233:Persons with Disabilities; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy; D006805:Human Experimentation / Q000941:ethics*; D006801:Humans; D062071:Infant, Extremely Premature; D007231:Infant, Newborn; D010100:Oxygen / Q000378:metabolism; D033282:Parental Consent / Q000941:ethics*; D011175:Positive-Pressure Respiration; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D059039:Standard of Care / Q000941:ethics*
chemical_list: D004967:Estrogens; D011663:Pulmonary Surfactants; D010100:Oxygen